Radiopharm Theranostics Limited (ASX:RAD)
Australia · Delayed Price · Currency is AUD 0.0060
0.00 (0.00%)
Oct 1, 2026, 4:10 PM AEST
Radiopharm Theranostics Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Operating Revenue | 2.77 | 3.63 | 0.3 | 0.29 | - |
Other Revenue | 10.73 | 9.37 | 1.29 | 5.92 | - |
| 13.5 | 13 | 1.59 | 6.21 | - | |
Revenue Growth | 3.85% | 716.81% | -74.37% | - | - |
Cost of Revenue | 47.2 | 31.11 | 21.61 | 19.53 | 7.49 |
Gross Profit | -33.7 | -18.11 | -20.02 | -13.32 | -7.49 |
Selling, General & Admin | 16.22 | 14.64 | 13.04 | 12.23 | 7.64 |
Operating Expenses | 18.62 | 16.53 | 15.68 | 15.27 | 12.44 |
Operating Income | -52.32 | -34.64 | -35.69 | -28.59 | -19.93 |
Interest Expense | -0.11 | -0.07 | -0.64 | -0.09 | -9.35 |
Interest & Investment Income | - | 0.89 | 0.05 | 0.15 | 0.01 |
Currency Exchange Gain (Loss) | - | 0.14 | 0.09 | -0.26 | -1.11 |
Other Non Operating Income (Expenses) | -0.87 | - | - | - | - |
EBT Excluding Unusual Items | -53.3 | -33.68 | -36.19 | -28.79 | -30.38 |
Gain (Loss) on Sale of Assets | - | - | -1.69 | - | - |
Asset Writedown | -5.27 | - | -1.48 | -3.1 | - |
Other Unusual Items | 1.67 | -4.56 | -8.49 | -2.68 | - |
Pretax Income | -56.9 | -38.24 | -47.85 | -34.57 | -30.38 |
Income Tax Expense | 0.05 | 0.1 | 0.1 | 0.04 | 0.04 |
Earnings From Continuing Operations | -56.95 | -38.34 | -47.95 | -34.61 | -30.42 |
Minority Interest in Earnings | 1.8 | - | - | - | - |
Net Income | -55.15 | -38.34 | -47.95 | -34.61 | -30.42 |
Net Income to Common | -55.15 | -38.34 | -47.95 | -34.61 | -30.42 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 3,081 | 2,081 | 386 | 306 | 181 |
Shares Outstanding (Diluted) | 3,081 | 2,081 | 386 | 306 | 181 |
Shares Change | 48.05% | 438.49% | 26.36% | 68.74% | - |
EPS (Basic) | -0.02 | -0.02 | -0.12 | -0.11 | -0.17 |
EPS (Diluted) | -0.02 | -0.02 | -0.12 | -0.11 | -0.17 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | -52.78 | -36.65 | -22.98 | -23.25 | -9.91 |
Free Cash Flow Per Share | -0.02 | -0.02 | -0.06 | -0.08 | -0.06 |
Gross Margin | -249.58% | -139.27% | - | -214.52% | - |
Operating Margin | -387.49% | -266.43% | -2242.42% | -460.41% | - |
Profit Margin | -408.44% | -294.90% | -3012.25% | -557.36% | - |
Free Cash Flow Margin | -390.92% | -281.85% | -1443.39% | -374.36% | - |
EBITDA | -49.61 | -32.05 | -32.57 | -25.29 | -16.94 |
EBITDA Margin | - | -246.46% | - | - | - |
D&A For EBITDA | 2.71 | 2.6 | 3.13 | 3.3 | 2.98 |
EBIT | -52.32 | -34.64 | -35.69 | -28.59 | -19.93 |
EBIT Margin | - | -266.43% | - | - | - |